Guided Therapeutics Inc. is developing a rapid and painless testing platform based on its patented biophotonics technology for the early detection of disease. The National Cancer Institute recently awarded the company $517,000 to fund the final year of a $2.5 million, three-year grant.
The grant provides the company with the necessary resources to help commercialize and bring to market the LuViva(TM) Advanced Cervical Scan and Cervical Guide single-patient-use disposable.
LuViva is a non-invasive device that provides immediate detection of cervical disease by scanning the cervix with light, instantly detecting and identifying cancer and pre-cancer. The technology is a stark contrast to Pap or HPV tests, in that it does not require laboratory analysis or a tissue sample.
LuViva is currently under pre-market approval (PMA) review by the U.S. Food and Drug Administration.
Since 2011, Guided Therapeutics has been awarded more than $6 million in six consecutive grants from the NCI to support the company’s development of new, pain-free test for detecting cervical disease.
“We view the continuation of the grant as further third-party validation of our technology and it provides additional non-dilutive resources to complete the regulatory process and begin manufacturing,” Mark L. Faupel, Ph.D., president and CEO of Guided Therapeutics stated in the press release.
For more information visit: www.guidedinc.com
Let us hear your thoughts below:
